Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Bautzner Landstraße 400, 01328 Dresden, Germany.
Universität Heidelberg, Anorganisch-Chemisches Institut, INF 270, 69120 Heidelberg, Germany.
Inorg Chem. 2023 Dec 18;62(50):20754-20768. doi: 10.1021/acs.inorgchem.3c02340. Epub 2023 Sep 14.
Octadentate and specifically nonadentate ligands with a bispidine scaffold (3,7-diazabicyclo[3.3.1]nonane) are known to be efficiently coordinated to a range of metal ions of interest in radiopharmaceutical chemistry and lead to exceedingly stable and inert complexes. Nonadentate bispidine (with a tridentate bipyridine acetate appended to N3 and a picolinate at N7) has been shown before to be an ideal chelator for In, Lu, and Ac, nuclides of interest for diagnosis and therapy, and a proof-of-principle study with an SSTR2-specific octreotate has shown potential for theranostic applications. We now have extended these studies in two directions. First, we present ligand derivative , in which the bipyridine acetate is substituted with terpyridine, a softer donor for metal ions with a preference for more covalency. did not fulfill the hopes because complexation is much less efficient. While for Bi and Pb the ligand is an excellent chelator with properties similar to those of , Lu and La show very slow and inefficient complexation with in contrast to , and Ac is not fully coordinated, even at an increased temperature (92% radiochemical yield at 80 °C, 60 min, [] = 10 M). These observations have led to a hypothesis for the complexation pathway that is in line with all of the experimental data and supported by a preliminary density functional theory analysis, which is important for the design of further optimized bispidine chelators. Second, the coordination chemistry of has been extended to Bi, La, and Pb, including solid state and solution structural work, complex stabilities, radiolabeling, and radiostability studies. All complexes of this ligand (La, Ac, Lu, Bi, In, and Pb), including nuclides for targeted α therapy (TAT), single-photon emission computed tomography, and positron emission tomography, are formed efficiently under physiological conditions, i.e., suitable for the labeling of delicate biological vectors such as antibodies, and the complexes are very stable and inert. Importantly, for TAT with Ac, the daughter nuclides Bi and Pb also form stable complexes, and this is important for reducing damage to healthy tissue.
具有双吡啶骨架(3,7-二氮杂双环[3.3.1]壬烷)的八齿和非齿状配体与一系列放射性药物化学中感兴趣的金属离子有效配位,并导致非常稳定和惰性的配合物。以前已经证明,非齿状双吡啶(在 N3 上带有三齿联吡啶乙酸盐,在 N7 上带有吡啶酸盐)是用于诊断和治疗的 In、Lu 和 Ac 核素的理想螯合剂,并且 SSTR2 特异性奥曲肽的原理研究表明了治疗应用的潜力。我们现在已经在两个方向上扩展了这些研究。首先,我们提出了配体衍生物,其中联吡啶乙酸盐被三吡啶取代,三吡啶是一种对金属离子更具共价性的更软的供体。虽然对于 Bi 和 Pb,该配体是一种出色的螯合剂,具有与类似的性质,但与相比,Lu 和 La 的配位非常缓慢且效率低下,并且 Ac 未完全配位,即使在升高的温度下(80°C,60 分钟,[]= 10M 时的放射性化学产率为 92%)。这些观察结果导致了一种与所有实验数据一致的配合物途径假说,并得到了初步密度泛函理论分析的支持,这对于进一步优化双吡啶螯合剂的设计很重要。其次,已经将的配位化学扩展到 Bi、La 和 Pb,包括固态和溶液结构研究、配合物稳定性、放射性标记和放射性稳定性研究。该配体的所有配合物(La、Ac、Lu、Bi、In 和 Pb),包括用于靶向α治疗(TAT)、单光子发射计算机断层扫描和正电子发射断层扫描的核素,都在生理条件下高效形成,即适合标记如抗体等精致的生物载体,并且这些配合物非常稳定和惰性。重要的是,对于 TAT 与 Ac,子核素 Bi 和 Pb 也形成稳定的配合物,这对于减少对健康组织的损害很重要。